Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Jing-Jin Electric Technologies
688280
5
Hangzhou Anysoft Information Technology
300571
US Stock MarketDetailed Quotes
PRLD Prelude Therapeutics
- 0.8866
- -0.0143-1.59%
Close Apr 28 16:00 ET
48.90MMarket Cap-0.53P/E (TTM)
0.9266High0.8524Low43.24KVolume0.8800Open0.9009Pre Close37.87KTurnover0.26%Turnover RatioLossP/E (Static)55.15MShares6.800052wk High0.37P/B14.93MFloat Cap0.610152wk Low--Dividend TTM16.84MShs Float95.3750Historical High--Div YieldTTM8.24%Amplitude0.6101Historical Low0.8750Avg Price1Lot Size
About Prelude Therapeutics Company
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Company Profile
SymbolPRLD
Company NamePrelude Therapeutics
Listing DateSep 25, 2020
Issue Price19.00
Founded2016
CEODr. Krishna Vaddi, PhD
MarketNASDAQ
Employees131
Fiscal Year Ends12-31
Address175 Innovation Boulevard
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19805
Phone1-302-467-1280
Websitehttp://www.preludetx.com
Company Executives
- Name
- Position
- Salary
- Dr. Krishna Vaddi, PhD
- Director and Chief Executive Officer
- 2.64M
- Peggy A. Scherle, PhD
- Chief Scientific Officer
- --
- Andrew P. Combs, PhD
- Chief Chemistry Officer
- --
- Dr. Jane Huang, M.D.
- President and Chief Medical Officer
- 1.65M
- Bryant D. Lim
- Chief Financial Officer, Chief Legal Officer and Corporate Secretary
- 1.61M
- Dr. Paul A. Friedman,M.D.
- Chairman of the Board
- 161.03K
- Mardi C. Dier
- Independent Director
- 147.03K
- Martin Babler
- Independent Director
- 134.53K
- Julian C. Baker
- Independent Director
- 140.03K
- Dr. Victor Sandor, C.M.,M.D.
- Independent Director
- 131.03K
- Dr. David P. Bonita, M.D.
- Independent Director
- 144.53K
Market Insights
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now